Sunshine Biopharma Q2 EPS $(9.94) Misses $(0.37) Estimate, Sales $9.30M Beat $9.00M Estimate
Portfolio Pulse from Benzinga Newsdesk
Sunshine Biopharma (NASDAQ:SBFM) reported Q2 earnings per share (EPS) of $(9.94), significantly missing the analyst estimate of $(0.37). However, the company reported sales of $9.30 million, beating the estimate of $9.00 million.
August 19, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Sunshine Biopharma reported a significant miss on Q2 EPS, with $(9.94) compared to the $(0.37) estimate. However, sales of $9.30 million beat the $9.00 million estimate.
The significant miss on EPS is likely to have a negative impact on the stock price in the short term, despite the sales beat. Investors may focus more on the large EPS miss.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100